KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.

ABSTRACT:

Background

Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience recurrence, with little effect from systemic therapies. Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue (KRAS) mutations have been reported to have an important role in tumorigenesis for human cancers, but there is limited knowledge regarding clinical relevance of KRAS status in endometrial carcinomas.

Methods

We have performed a comprehensive and integrated characterisation of genome-wide expression related to KRAS mutations and copy-number alterations in primary- and metastatic endometrial carcinoma lesions in relation to clinical and histopathological data. A primary investigation set and clinical validation set was applied, con

SUBMITTER: Birkeland E 

PROVIDER: S-EPMC3516681 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature